Advent Life Sciences

Advent Venture Partners is one of Europe's most established venture and growth capital investors, founded in 1981 and headquartered in London, United Kingdom. With over EUR 500 million in fund commitments under management and 151 investments over its history, the firm has backed innovative businesses across the United Kingdom, continental Europe, and the United States for more than four decades. Advent invests across two core practices: technology and growth capital, and life sciences through its dedicated Advent Life Sciences arm. The firm focuses on early and mid-stage companies across enterprise software, healthcare, drug discovery and development, diagnostics, consumer, and media, deploying initial checks of $3 million to $10 million and leading rounds. Advent's portfolio carries a strong exit track record spanning 2 IPOs and 21 acquisitions, with notable companies including Yelp, Wiz, and Farfetch. The current active portfolio comprises 28 companies. Advent's longevity reflects a consistent thesis: back founders with differentiated technology at a stage when capital and strategic guidance make the biggest difference, then support companies through successive growth phases. The firm's dual structure — one arm focused on technology and growth capital, the other on life sciences — allows it to maintain genuine sector depth in two complex, high-conviction verticals while operating with the speed and conviction of a specialist investor.